Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) announced its quarterly earnings results on Thursday. The biotechnology company reported ($1.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.28) by $0.18, Bloomberg Earnings reports.

Eiger BioPharmaceuticals (NASDAQ:EIGR) traded down $0.10 during midday trading on Friday, reaching $10.90. The company had a trading volume of 23,629 shares, compared to its average volume of 54,860. Eiger BioPharmaceuticals has a 12-month low of $6.10 and a 12-month high of $13.95. The company has a quick ratio of 7.01, a current ratio of 7.01 and a debt-to-equity ratio of 0.72.

Several equities analysts have recently commented on EIGR shares. Zacks Investment Research lowered Eiger BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Wedbush reissued a “buy” rating on shares of Eiger BioPharmaceuticals in a research note on Wednesday, October 25th. Piper Jaffray Companies restated a “buy” rating and set a $36.00 price target on shares of Eiger BioPharmaceuticals in a report on Tuesday, August 15th. Oppenheimer Holdings, Inc. restated a “buy” rating and set a $34.00 price target on shares of Eiger BioPharmaceuticals in a report on Monday, September 25th. Finally, ValuEngine upgraded Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Eiger BioPharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $30.43.

In related news, Director Jeffrey S. Glenn purchased 15,000 shares of the company’s stock in a transaction on Friday, September 1st. The stock was bought at an average price of $9.53 per share, with a total value of $142,950.00. Following the completion of the transaction, the director now owns 31,355 shares of the company’s stock, valued at approximately $298,813.15. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 28.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Eiger BioPharmaceuticals, Inc. (EIGR) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/11/10/eiger-biopharmaceuticals-inc-eigr-releases-quarterly-earnings-results-beats-estimates-by-0-18-eps.html.

About Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Earnings History for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.